

CONTENTS

Theme of this month : A New Definition of Steatotic Liver Disease : MASLD

Editorial	<i>Takumi Kawaguchi</i>	733
Natural History of Patients with MASLD in Japan	<i>Tsubasa Tsutsumi, et al</i>	736
Impact of Host Genetic Factors for Pathology of MASLD	<i>Norio Akuta</i>	742
Genetic Polymorphisms of Diabetes and Clinical Features in Patients with MASLD	<i>Tomomi Kogiso</i>	750
Hepatic Energy Metabolism and Inhibition of VLDL Secretion	<i>Eiji Kakazu</i>	757
Modulation of Lipid Metabolism in the Pathogenesis of MASLD/MASH	<i>Kazuyoshi Kon</i>	762
The Association between Fatty Acid Composition and Metabolic Dysfunction-associated Steatotic Liver Disease	<i>Teruki Miyake, et al</i>	768
MASLD and Oxidative Stress	<i>Kohei Oda</i>	773
Ultrasonography in MASLD	<i>Masahito Nakano, et al</i>	779
MRI as a Diagnostic Tool for MASLD	<i>Takashi Kobayashi, Masato Yoneda, et al</i>	785
Screening of High-risk Group of Hepatocellular Carcinoma —Identification of High-risk Group of HCC : FIB-3 Index	<i>Akiko Wakuta, Kazuya Kariyama, et al</i>	792
Inhibition of Hydroxynonenal(HNE)-induced Hepatocyte Degeneration by Alda-1	<i>Hidenori Kido, et al</i>	797
Gut Barrier Treatment with Lubiprostone	<i>Takaomi Kessoku, et al</i>	804
Novel Selective PPAR α Modulator Pemafibrate for MASLD/MASH	<i>Yuichiro Eguchi</i>	813

Series**How to Use the Kyoto Classification of Gastritis :**

Does the Morphology of Residual Oxyntic Mucosa Have Any Meaning?

Yasuhiko Maruyama, et al 823**Endoscopy : A Case of Varioliform Gastritis-like Lesion in *H. pylori***

Uninfected Mucosa that Could Be Qualitatively Diagnosed by

Administration of Antacid

Hidetoshi Akiyama, et al 832**NIHON MEDICAL CENTER, Inc.**

1-64 Kanda-jinbo-cho, Chiyoda-ku, Tokyo 101-0051, JAPAN